Cetuximab (Erbitux®, Imclone/Merck GaA), a highly active IgG1 monoclonal antibody that specifically targets the epidermal growth factor (EGF), in combination with the chemotherapeutic agents oxaliplatin (Eloxatin®, Sanofi Aventis) and capecitabine (Xeloda®, Roche) provides inter­esting efficacy results without compromising safety, provid­ing a new option in the first-line treatment of metastatic colorectal cancer, according to data from a clinical trial presented at the 42nd Annual Meeting of the American Society of Clinical Oncology.
Go to Previous Page
Go to Next Page